CABA FINANCIAL STATEMENTS

Cabaletta Bio Inc — balance sheet, income statement and cash flow trends

CABACabaletta Bio Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue0 $-100.0%

Gross Profit148 K $—

Operating Income-179.4 M $—

EBITDA-171.6 M $—

Net Income-175.4 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CABA	-100.0%	—	—	—
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
RTALB	24.0%	35.1%	9.0%	136.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CABA	-100.0%	—	—	—
EDIT	8.0%	5.8%	-258.7%	-281.6%
LCTX	54.6%	98.0%	-291.9%	-434.4%
FATE	-52.6%	-415.8%	-1,859.1%	-2,056.8%
FHTX	20.1%	22.3%	-257.0%	-266.9%
VNDA	8.2%	92.5%	-62.6%	-110.0%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity103.3 M $70%
Current Liabilities41.5 M $28%
Long-term Liabilities3.3 M $2%

Key Figures

YoY change

Total Assets148.1 M $-10.3%

Total Liabilities44.8 M $+2.9%

Total Equity103.3 M $-15.0%

Cash & ST Investments116.6 M $-11.5%

Total Debt26.5 M $-8.1%

Net Debt-90.2 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CABA	2.95	25.6%	0.53	69.7%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
RTALB	1.21	1.2%	0.90	84.9%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CABA	2.95	25.6%	0.53	69.7%
EDIT	3.22	1,632.8%	0.52	3.0%
LCTX	6.89	4.4%	1.18	49.2%
FATE	5.85	42.7%	0.83	63.1%
FHTX	2.92	-55.0%	1.97	-34.4%
VNDA	2.16	4.7%	1.39	64.8%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-142.8 M $—

Capital Expenditures444 K $-79.7%

Free Cash Flow-143.3 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CABA	—	—	—	81.4%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
RTALB	58.5%	88.6%	10.8%	42.9%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CABA	—	—	—	81.4%
EDIT	-363.1%	-364.6%	1.5%	129.0%
LCTX	-149.6%	-150.9%	1.3%	34.4%
FATE	-1,632.3%	-1,711.4%	79.1%	79.4%
FHTX	-309.7%	-309.7%	0.1%	116.0%
VNDA	-58.1%	-58.5%	0.4%	52.8%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on CABA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.